About Beximco Pharma
Beximco Pharma aspires to become a nationally admired and globally reputed generic pharmaceutical company, committed to enhancing human health and life.
Beximco Pharmaceuticals Ltd (BPL) is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) in Bangladesh. Beximco Pharma is the flagship company of Beximco Group, the largest private sector industrial conglomerate in Bangladesh, and remains the only Bangladeshi company with an AIM listing on the London Stock Exchange.
The company is the largest exporter of pharmaceuticals in the country and its state-of-the-art manufacturing facilities are certified by global regulatory bodies of Australia, European Union, Gulf nations, Brazil, among others. The company is consistently building upon its portfolio and currently producing more than four hundred products in different dosage forms covering broader therapeutic categories which include antibiotics, antihypertensives, antidiabetics, antireretrovirals, anti asthma inhalers etc, among many others.
With decades of contract manufacturing experience with global MNCs, skilled manpower and proven formulation capabilities, the company has been building a visible and growing presence across the continents offering high quality generics at the most affordable cost.
Ensuring access to quality medicines is the powerful aspiration that motivates more than 2,500 employees of the organization, and each of them is guided by the same moral and social responsibilities the company values most.
Today Beximco Pharma is building its presence across five continents and is the only Bangladeshi company to market pharmaceutical products in the USA. The company has a visible and growing presence in emerging market.
Weâ€™ve built Beximco Pharma into one of the most trusted pharmaceutical companies in the country by delivering solid returns to our shareholders, and helping patients with life-altering conditions so that they may live their lives to the fullest.
Beximco Pharma started its journey back in the 1970â€™s. Today the company has grown to become one of the largest exporters of medicines in the country; employing over 2,500 people and expanding its presence across many regions of the world.
Letâ€™s take a look at Beximco Pharmaâ€™s milestones along the way ...
2011: GMP certification from AGES, Austria (Austrian Agency for Health and Food Safety)
2010 : The only pharmaceutical company in Bangladesh to enter the US market through the acquisition of an Abbreviated New Drug Application (ANDA) for a product; Received GMP Accreditation from INVIMA, Colombia
2009 : Only Bangladeshi company to receive GMP Certification from ANVISA, Brazil; ION unit was launched for producing injectables, ophthalmics and nebulizer solutions
2008 : First Bangladeshi company to receive GMP Clearance from Therapeutic Goods Administration (TGA) Australia, and Gulf Central Committee for Drug Registration, for GCC states; Technology transfer arrangement to manufacture Rocheâ€™s ARV drug Saquinavir
2007 : Oral Solid Dosage facility was commissioned according to US FDA standards
2006 : Launched CFC free HFA inhalers for the first time in Bangladesh
2005 : Only company in Bangladesh to be listed on the Alternative Investment Market (AIM) of London Stock Exchange (LSE) through issuance of GDRs
2003 : First and only company to introduce anti-retroviral (ARV) drugs in Bangladesh
2001 : First and only Bangladeshi company to enter Singapore, one of the most regulated markets in Asia
2000 : Only company to achieve â€˜National Export Trophy (Gold)â€™ for the third time
1996 : IV unit (former Beximco Infusions Ltd.) received ISO 9001 Certification from TUV-Cert, Germany
1993 : Russia became the first export destination for formulation products
1992 : Export operation started with APIs
1985 : Listed on Dhaka Stock Exchange
1983 : Launched its own formulation brands
1980 : Started manufacturing products of Bayer AG, Germany and Upjohn Inc., USA, under license agreements
1976 : Company incorporated